A Phase 3 interventional study of LY2189265 and Liraglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 57 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 24th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 599 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 48th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 87th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks
Drug: LY2189265 · Drug: Metformin
Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks
Drug: Liraglutide · Drug: Metformin
Administered SC
Also known as: Dulaglutide
Administered SC
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means of the glycosylated hemoglobin A1c (HbA1c) change from baseline to the primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect, and baseline HbA1c as covariates, via a mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).
Time frame: Baseline, 26 Weeks
Change From Baseline in Body Weight at 26 Weeks
LS means of the weight change from baseline to primary endpoint at Week 26 were calculated using analysis of covariance (ANCOVA) with HbA1c Strata, country, and treatment as fixed effects and baseline body weight as a covariate.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in Body Mass Index (BMI) at 26 Weeks
BMI is an estimate of body fat based on body weight divided by height squared. LS means of the BMI change from baseline to primary endpoint at Week 26 were calculated using ANCOVA with HbA1c Strata, country, and treatment as fixed effects and baseline BMI as a covariate.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks
LS means of the FPG from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FPG as covariates, via ANCOVA with LOCF.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks
The SMPG data were collected at the following 7 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; and bedtime. The mean of the 7 time points (Daily Mean) was also calculated. LS means of the SMPG change from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, HbA1c strata, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG as a covariate, via a MMRM analysis using REML.
Time frame: Baseline, 26 Weeks
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) ≤6.5% or <7% at 26 Weeks
The percentage of participants who achieved the target HbA1c values at the primary endpoint were analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes pooled country, treatment, visit, treatment-by-visit interaction, and baseline HbA1c as continuous covariates.
Time frame: Up to 26 Weeks
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means of the HOMA2-%B change from baseline to primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline HOMA2-%B value as covariate, via an ANCOVA analysis using LOCF.
Time frame: Baseline, Up to 26 Weeks
Number of Participants With Reported and Adjudicated Cardiovascular Events
Deaths and nonfatal cardiovascular (CV) adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal CV AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with reported CV events, number of participants with nonfatal CV events confirmed by adjudication, and number of deaths confirmed by adjudication are summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline up to 26 Weeks
Change From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks
ECG HR was measured. LS means of change from baseline were analyzed using ANCOVA with HbA1c strata, country, and treatment as fixed effects and baseline HR as a covariate.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in Electrocardiogram (ECG) Parameters PR and QTcF (Fridericia's) Intervals at 26 Weeks
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. QTcF is the measure of the time between the start of the Q wave and the end of the T wave adjusted using Fridericia's formula. PR is the interval between the P wave and the QRS complex. These parameters were calculated from electrocardiogram (ECG) data. LS means of change from baseline for the PR and QTcF intervals will be analyzed using the MMRM similar to MMRM model for primary outcome, using corresponding baseline and HbA1c strata. Only ECGs obtained at scheduled visits will be used in these summaries and analyses.
Time frame: Baseline, 26 Weeks
Change From Baseline in Heart Rate (HR) at 26 Weeks
Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the MMRM model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in Blood Pressure (BP) at 26 Weeks
Descriptive statistics for the actual measurements and change from baseline for sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline BP as a covariate, and participant as a random effect.
Time frame: Baseline, 26 Weeks
Number of Participants With Adjudicated Acute Pancreatitis Events
The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 26 weeks (including a 30-day follow up). Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline up to 30 Weeks
Change From Baseline in Calcitonin at 26 Weeks
A summary of participants having changes in calcitonin values from baseline to primary endpoint of 26 weeks is presented.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in Lipase at 26 Weeks
A summary of participants having changes in lipase evaluation from baseline to primary endpoint of 26 weeks is presented.
Time frame: Baseline, Up to 26 Weeks
Change From Baseline in Amylase at 26 Weeks
A summary of participants having changes in amylase evaluation from baseline to primary endpoint of 26 weeks is presented.
Time frame: Baseline, Up to 26 Weeks
Percentage of Participants With Self-Reported Hypoglycemia Events
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a plasma glucose \[PG\] concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.
Time frame: Baseline through 26 Weeks
Rate of Hypoglycemic Events Adjusted Per 30 Days
HE were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). The hypoglycemia rate per 30 days was calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.
Time frame: Baseline through 26 Weeks
Number of Participants With Allergic or Hypersensitivity Reactions
Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose
LY2189265 (dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation in dulaglutide-treated participants. A participant was considered to have treatment emergent LY2189265 ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The number of participants with treatment-emergent LY2189265 ADA from postbaseline to follow up were summarized.
Time frame: Baseline up to 4 Weeks Post Last Dose of Study Drug
Percent Change From Baseline in Lipid Parameters at 26 Weeks
A summary of percent change in lipid parameters (total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], very low-density lipoprotein cholesterol \[VLDL\], and triglycerides) from baseline to primary endpoint of 26 weeks is presented. LS means of the lipid parameter from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and lipid parameter baseline as covariates, via ANCOVA with LOCF.
Time frame: Baseline, Up to 26 Weeks
| Milestone | LY2189265 | Liraglutide |
|---|---|---|
| Started | 299 | 300 |
| Received at least one dose of study drug | 299 | 300 |
| Completed | 269 | 269 |
| Not completed | 30 | 31 |
| Withdrew: Adverse event | 18 | 18 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Abnormal laboratory measure | 3 | 0 |
Least Squares (LS) means of the glycosylated hemoglobin A1c (HbA1c) change from baseline to the primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect, and baseline HbA1c as covariates, via a mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.42 ± 0.05 | -1.36 ± 0.05 |
LS means of the weight change from baseline to primary endpoint at Week 26 were calculated using analysis of covariance (ANCOVA) with HbA1c Strata, country, and treatment as fixed effects and baseline body weight as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Body Weight at 26 Weeks | -2.90 ± 0.22 | -3.61 ± 0.22 |
BMI is an estimate of body fat based on body weight divided by height squared. LS means of the BMI change from baseline to primary endpoint at Week 26 were calculated using ANCOVA with HbA1c Strata, country, and treatment as fixed effects and baseline BMI as a covariate.
| kilograms/square meter (kg/m^2) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at 26 Weeks | -1.05 ± 0.08 | -1.30 ± 0.08 |
LS means of the FPG from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FPG as covariates, via ANCOVA with LOCF.
| milligrams/deciliter (mg/dL) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks | -34.81 ± 2.13 | -34.25 ± 2.11 |
The SMPG data were collected at the following 7 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; and bedtime. The mean of the 7 time points (Daily Mean) was also calculated. LS means of the SMPG change from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, HbA1c strata, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG as a covariate, via a MMRM analysis using REML.
| mg/dL | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks | -40.76 ± 1.50 | -38.51 ± 1.45 |
The percentage of participants who achieved the target HbA1c values at the primary endpoint were analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes pooled country, treatment, visit, treatment-by-visit interaction, and baseline HbA1c as continuous covariates.
| percentage of participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| HbA1c levels ≤6.5% | 54.6 | 50.9 |
| HbA1c levels <7.0% | 68.3 | 67.9 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means of the HOMA2-%B change from baseline to primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline HOMA2-%B value as covariate, via an ANCOVA analysis using LOCF.
| percentage of HOMA2-%B | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks | 37.03 ± 2.26 | 35.59 ± 2.27 |
Deaths and nonfatal cardiovascular (CV) adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal CV AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with reported CV events, number of participants with nonfatal CV events confirmed by adjudication, and number of deaths confirmed by adjudication are summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Any reported CV events | 0 | 3 |
| Any adjudicated nonfatal CV events | 0 | 1 |
| Any confirmed adjudicated deaths | 0 | 0 |
ECG HR was measured. LS means of change from baseline were analyzed using ANCOVA with HbA1c strata, country, and treatment as fixed effects and baseline HR as a covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks | 1.9 ± 0.55 | 4.1 ± 0.54 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. QTcF is the measure of the time between the start of the Q wave and the end of the T wave adjusted using Fridericia's formula. PR is the interval between the P wave and the QRS complex. These parameters were calculated from electrocardiogram (ECG) data. LS means of change from baseline for the PR and QTcF intervals will be analyzed using the MMRM similar to MMRM model for primary outcome, using corresponding baseline and HbA1c strata. Only ECGs obtained at scheduled visits will be used in these summaries and analyses.
| milliseconds (msec) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| PR interval (n=270, 278) | 3.8 ± 0.81 | 3.3 ± 0.80 |
| QTcF interval (n=273, 284) | 0.39 ± 0.90 | -0.72 ± 0.89 |
Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the MMRM model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.
| bpm | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Heart Rate (HR) at 26 Weeks | 2.37 ± 0.4 | 3.12 ± 0.4 |
Descriptive statistics for the actual measurements and change from baseline for sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline BP as a covariate, and participant as a random effect.
| milliliters of mercury (mmHg) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Sitting DBP | -0.22 ± 0.4 | -0.31 ± 0.4 |
| Sitting SBP | -3.36 ± 0.7 | -2.82 ± 0.7 |
The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 26 weeks (including a 30-day follow up). Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Number of Participants With Adjudicated Acute Pancreatitis Events | 0 | 0 |
A summary of participants having changes in calcitonin values from baseline to primary endpoint of 26 weeks is presented.
| picograms/milliliter (pcg/mL) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Calcitonin at 26 Weeks | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
A summary of participants having changes in lipase evaluation from baseline to primary endpoint of 26 weeks is presented.
| units/liter (U/L) | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Lipase at 26 Weeks | 7.0 (0.5 to 17.5) | 11.0 (2.0 to 23.0) |
A summary of participants having changes in amylase evaluation from baseline to primary endpoint of 26 weeks is presented.
| U/L | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Change From Baseline in Amylase at 26 Weeks | 7.0 (0.0 to 14.0) | 6.0 (0.0 to 13.0) |
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a plasma glucose \[PG\] concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Documented symptomatic HE | 2.7 | 2.7 |
| Asymptomatic HE | 6.7 | 3.3 |
| Severe HE | 0.0 | 0.0 |
| Nocturnal HE | 1.3 | 2.0 |
| Probable symptomatic HE | 1.0 | 1.0 |
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.
| percentage of participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia | 0.3 | 1.0 |
HE were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). The hypoglycemia rate per 30 days was calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| number of events/participant/30 days | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Total HE | 0.03 ± 0.12 | 0.04 ± 0.25 |
| Documented symptomatic HE | 0.01 ± 0.08 | 0.02 ± 0.17 |
| Asymptomatic HE | 0.02 ± 0.07 | 0.01 ± 0.08 |
| Severe HE | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Nocturnal HE | 0.01 ± 0.05 | 0.01 ± 0.10 |
| Probable symptomatic HE | 0.00 ± 0.02 | 0.01 ± 1.12 |
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.
| weeks | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia | NA (0.975 to 1.000) | NA (0.966 to 0.996) |
Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| Number of Participants With Allergic or Hypersensitivity Reactions | 1 | 5 |
LY2189265 (dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation in dulaglutide-treated participants. A participant was considered to have treatment emergent LY2189265 ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The number of participants with treatment-emergent LY2189265 ADA from postbaseline to follow up were summarized.
| participants | 1.5 mg LY2189265 |
|---|---|
| Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose | 3 |
A summary of percent change in lipid parameters (total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], very low-density lipoprotein cholesterol \[VLDL\], and triglycerides) from baseline to primary endpoint of 26 weeks is presented. LS means of the lipid parameter from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and lipid parameter baseline as covariates, via ANCOVA with LOCF.
| percent | LY2189265 | Liraglutide |
|---|---|---|
| Total cholesterol (n=286, 284) | -1.64 ± 1.18 | 0.67 ± 1.18 |
| HDL-C (n=286, 284) | 6.21 ± 1.02 | 6.46 ± 1.02 |
| LDL-C (n=276, 276) | -1.09 ± 2.17 | 3.20 ± 2.15 |
| VLDL (n=276, 276) | 1.56 ± 2.63 | 2.92 ± 2.60 |
| Triglycerides (n=286, 284) | 0.59 ± 2.76 | 1.35 ± 2.76 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg LY2189265 | — | 5/299 (1.7%) | 185/299 (61.9%) |
| 1.8 mg Liraglutide | — | 11/300 (3.7%) | 186/300 (62%) |
| Event | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/299 | 0/300 |
| BronchopneumoniaInfections and infestations | 1/299 | 0/300 |
| Ankle fractureInjury, poisoning and procedural complications | 1/299 | 0/300 |
| FallInjury, poisoning and procedural complications | 1/299 | 0/300 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/299 | 0/300 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/299 | 0/300 |
| EpilepsyNervous system disorders | 1/299 | 0/300 |
| SchizophreniaPsychiatric disorders | 1/299 | 0/300 |
| Angina pectorisCardiac disorders | 0/299 | 1/300 |
| TachyarrhythmiaCardiac disorders | 0/299 | 1/300 |
| Event | 1.5 mg LY2189265 | 1.8 mg Liraglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 61/299 | 54/300 |
| DiarrhoeaGastrointestinal disorders | 36/299 | 36/300 |
| VomitingGastrointestinal disorders | 21/299 | 25/300 |
| HeadacheNervous system disorders | 22/299 | 25/300 |
| DyspepsiaGastrointestinal disorders | 24/299 | 18/300 |
| NasopharyngitisInfections and infestations | 23/299 | 21/300 |
| Decreased appetiteMetabolism and nutrition disorders | 16/299 | 20/300 |
| ConstipationGastrointestinal disorders | 11/299 | 17/300 |
| Back painMusculoskeletal and connective tissue disorders | 11/299 | 15/300 |
Participants who were randomized and received at least 1 dose of LY2189265 or Liraglutide
| Age, Continuous(years) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Mean | 56.49 ± 9.34 | 56.81 ± 9.91 | 56.65 ± 9.63 |
| Sex: Female, Male(Participants) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Female | 161 | 151 | 312 |
| Male | 138 | 149 | 287 |
| Ethnicity (NIH/OMB)(Participants) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 75 | 72 | 147 |
| Not Hispanic or Latino | 221 | 223 | 444 |
| Unknown or Not Reported | 3 | 5 | 8 |
| Race (NIH/OMB)(Participants) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 20 | 23 | 43 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 16 | 37 |
| White | 256 | 259 | 515 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| United States | 97 | 97 | 194 |
| Czech Republic | 27 | 28 | 55 |
| Hungary | 21 | 19 | 40 |
| Mexico | 20 | 21 | 41 |
| Slovakia | 20 | 22 | 42 |
| Puerto Rico | 3 | 4 | 7 |
| Poland | 39 | 42 | 81 |
| Spain | 24 | 24 | 48 |
| Romania | 20 | 17 | 37 |
| Germany | 28 | 26 | 54 |
| Body Weight(kilograms (kg)) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Mean | 93.82 ± 18.23 | 94.35 ± 18.96 | 94.09 ± 18.58 |
| Body Mass Index (BMI)(kilograms per meter squared (kg/m^2)) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Mean | 33.50 ± 5.07 | 33.62 ± 5.16 | 33.56 ± 5.11 |
| Glycosylated hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | LY2189265 | Liraglutide | Total |
|---|---|---|---|
| Mean | 8.06 ± 0.81 | 8.05 ± 0.79 | 8.05 ± 0.80 |
1 further baseline measures are reported on the registry.
The record gives a start of Jun 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 11 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide